Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Oncotarget|April 30, 2016
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimenAnthony Kong, Daniel Rea, Samreen Ahmed, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 21, 2017
The significance of Trk receptors in pancreatic cancerMatthew D Johnson, Brandon Stone, Bryan J Thibodeau, et al.European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trialSiow Ming Lee, Madeleine Hewish, Samreen Ahmed, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid TumorsNeeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatmentJeroen W G Derksen, Graham W Warren, Karin Jordan, et al.European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 StudyRoy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.The New England Journal of Medicine|November 8, 2023
Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)Siow Ming Lee, Mary Falzon, Fiona Blackhall, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.Pageof 6